News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
New and experimental hepatitis C treatment
US: do not mix Merck hepatitis pill with HIV drugs

U.S. drug regulators are changing the label for Merck & Co Inc's recently approved Victrelis treatment for hepatitis C to show it should not be taken with some widely used HIV medicines.

Published
27 April 2012
From
Reuters
New and experimental hepatitis C treatment
No Relevant Interactions Between Telaprevir and Two Newest Nonnucleosides Rilpivirine & Etravirine

Taking the anti-HCV protease inhibitor telaprevir with the nonnucleoside rilpivirine significantly boosted rilpivirine concentrations, but not to an extent judged clinically relevant, according to results of a study in healthy volunteers. Both rilpivirine and etravirine lowered concentrations of telaprevir, but again not to clinically relevant extents.

Published
20 April 2012
From
NATAP
Drug interactions and pharmacokinetics
Genetic testing for drug intolerance

Intolerance to a drug is something most people learn about themselves only after it's prescribed. "There are some tumour drugs, for certain cancers, that 70% of the population won't respond to. For some asthma drugs, it's 40%," says Dingermann, who has been collecting research on the topic for the past four years.

Published
16 April 2012
From
The Guardian
New and experimental hepatitis C treatment
What You Don’t Know, You Can Sell: Merck’s Cavalier Attitude Towards the Welfare of HIV/HCV Coinfected Patients

Despite outrage from activists, Merck refused to study drug-drug interactions (DDIs) between boceprevir (Victrelis), their HCV protease inhibitor, and drugs commonly used to treat HIV, putting coinfected study volunteers at risk for drug-drug interactions in their own clinical trial.

Published
10 April 2012
From
TAG
Hepatitis C treatment
Studies look at interactions between new hepatitis C drugs and HIV antiretrovirals

Drug-drug interactions between direct-acting antiviral agents for hepatitis C and some antiretroviral medications used to treat HIV are common, but are often modest and can be managed

Published
14 March 2012
By
Liz Highleyman
Malaria
Lopinavir/ritonavir cuts malaria risk in children with HIV

HIV-infected children in Tororo, Uganda, an area of high malaria transmission, on a lopinavir/ritonavir (LPV/r, or Kaletra)-based antiretroviral (ART) regimen had a significantly lower risk of getting

Published
07 March 2012
By
Carole Leach-Lemens
PrEP
Once-a-month HIV drug maintains good levels for prevention; few side-effects so far

The first trial in humans of an injectable, once-a-month formulation of an HIV drug has found that drug levels were maintained at a level that should in

Published
07 March 2012
By
Gus Cairns
PrEP
Four doses of PrEP a week may be enough to protect

Further testing of drug levels in the blood and immune cells of gay men participating in the iPrEx trial of tenofovir/FTC (Truvada) pre-exposure prophylaxis (PrEP) has

Published
06 March 2012
By
Gus Cairns
Drug interactions and pharmacokinetics
FDA updates guidance for use of HIV and hepatitis C protease inhibitors with statins

Medicine regulatory authorities in the US have updated their recommendations concerning possible interactions between statins and protease inhibitors used to treat HIV and hepatitis C. Guidance from

Published
04 March 2012
By
Michael Carter
Side-effects
Severe nevirapine rash linked to slow clearance of drug

The risk of severe rash when taking the antiretroviral drug nevirapine is greater in women who clear the drug from their bloodstreams slowly, and clearance of the drug

Published
20 February 2012
By
Carole Leach-Lemens
← Prev12345...14Next →

Filter by country